ZRSR2

Across TCGA pan-cancer cohorts, ZRSR2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZRSR2 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZRSR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZRSR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LIHC, and UCEC are the cancer types where ZRSR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.048	0.814	<.001	30	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.028	18	view →
HNSC	DFS	Median	All	0.168	0.626	.021	15	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZRSR2–LUAD (OS)

Open the LUAD breakdown →